Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Drug manufacturer Novo Nordisk announced a new experimental weight-loss pill to treat obesity in development called amycretin ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

The drug, called amycretin and codenamed NN9487, is a dual agonist that targets both GLP-1 and amylin and is being developed in both oral and subcutaneous injection formulations. The oral form has ...

The biotech had tested the oral asset, dubbed VK2735, at doses ranging from 2.5 mg up to 100 mg. Viking already revealed back in March that 25% of the eight patients who received 20-mg doses saw their ...

Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...

The drug, called amycretin, helped volunteer patients lose a whopping 13 percent of their body weight over just 12 weeks. That means the new pill may be even more effective than the company's ...

Why? Results from a Phase I trial of a new amycretin pill indicate that a highly effective and less intrusive weight loss drug is on the way, providing an alternative to the injection-based Ozempic.

Analysts led by Prakhar Agrawal noted that Novo Nordisk has not launched an oral version of its semaglutide despite a positive Phase 3 trial and is awaiting subcutaneous amycretin data before ...

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...

But fear not, Novo Nordisk is now developing a possibly cheaper weight loss medication, a pill called amycretin, which has indications that it could be even more effective in helping people lose ...